HRP20201967T1 - Heterociklički spojevi i njihova uporaba - Google Patents
Heterociklički spojevi i njihova uporaba Download PDFInfo
- Publication number
- HRP20201967T1 HRP20201967T1 HRP20201967TT HRP20201967T HRP20201967T1 HR P20201967 T1 HRP20201967 T1 HR P20201967T1 HR P20201967T T HRP20201967T T HR P20201967TT HR P20201967 T HRP20201967 T HR P20201967T HR P20201967 T1 HRP20201967 T1 HR P20201967T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical formulation
- formulation according
- pharmaceutically acceptable
- omecamtiv
- controlled release
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 238000013270 controlled release Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000000945 filler Substances 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 229960003943 hypromellose Drugs 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 238000005469 granulation Methods 0.000 claims 3
- 230000003179 granulation Effects 0.000 claims 3
- RFUBTTPMWSKEIW-UHFFFAOYSA-N omecamtiv mecarbil Chemical compound C1CN(C(=O)OC)CCN1CC1=CC=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1F RFUBTTPMWSKEIW-UHFFFAOYSA-N 0.000 claims 3
- 229950001617 omecamtiv mecarbil Drugs 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 claims 2
- 238000005461 lubrication Methods 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (15)
1. Farmaceutska formulacija koja sadrži:
farmaceutski prihvatljivu sol omekamtiv mekarbila ili njezin farmaceutski prihvatljiv hidrat;
sredstvo za kontrolirano oslobađanje;
sredstvo za modificiranje pH odabrano iz skupine koja se sastoji od fumarne kiseline, vinske kiseline, glutaminske kiseline i bilo koje njihove kombinacije; punilo; i
lubrikant.
2. Farmaceutska formulacija prema patentnom zahtjevu 1, naznačena time što farmaceutski prihvatljiva sol omekamtiv mekarbila ili njezin farmaceutski prihvatljiv hidrat je omekamtiv mekarbil dihidroklorid hidrat.
3. Farmaceutska formulacija prema patentnom zahtjevu 1 ili 2, naznačena time što je sredstvo za modificiranje pH fumarna kiselina.
4. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 1-3, naznačena time što se punilo bira od škroba, laktoze, manitola, derivata celuloze, kalcijevog fosfata, šećera i bilo koje njihove kombinacije.
5. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 1-4, naznačena time što sredstvo za kontrolirano oslobađanje sadrži hipromelozu koja ima viskoznost od 100000 mPa.s pri 2% koncentraciji u vodi na 20°C.
6. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 1-4, naznačena time što sredstvo za kontrolirano oslobađanje sadrži hipromelozu koja ima viskoznost od 100 mPa.s pri 2% koncentraciji u vodi na 20°C.
7. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 1-4, naznačena time što je sredstvo za kontrolirano oslobađanje smjesa hipromeloze koja ima viskoznost od 100000 mPa.s pri 2% koncentraciji u vodi na 20°C i hipromeloze koja ima viskoznost od 100 mPa.s pri 2% koncentraciji u vodi na 20°C.
8. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 1-7, naznačena time što je punilo kombinacija mikrokristalne celuloze i laktoze monohidrata.
9. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 1-8, naznačena time što je lubrikant magnezijev stearat.
10. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 1-9, naznačena time što je formulacija u obliku tablete.
11. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 1-10 naznačena time što sadrži:
3-30% m/m farmaceutski prihvatljive soli omekamtiv mekarbila ili njezinog farmaceutski prihvatljivog hidrata;
15-35% m/m sredstva za kontrolirano oslobađanje;
20-45% m/m sredstva za modificiranje pH;
25-65% m/m punila; i
0,1-1,0% m/m lubrikanta.
12. Postupak za proizvodnju farmaceutske formulacije prema patentnom zahtjevu 1, naznačen time što sadrži:
miješanje smjese koja sadrži farmaceutski prihvatljivu sol omekamtiv mekarbila ili njezin farmaceutski prihvatljiv hidrat, sredstvo za kontrolirano oslobađanje, sredstvo za modificiranje pH, i punilo;
podmazivanje pomiješane smjese pomoću lubrikanta;
granuliranje podmazane smjese;
podmazivanje nastale granulacije pomoću lubrikanta; i komprimiranje podmazane granulacije u željeni oblik.
13. Postupak prema patentnom zahtjevu 12, naznačen time što je farmaceutski prihvatljiva sol omekamtiv mekarbila ili njezin farmaceutski prihvatljiv hidrat omekamtiv mekarbil dihidroklorid hidrat.
14. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 1-11 naznačena time što je za uporabu u liječenju bolesti odabrane između akutnog zatajenja srca i kroničnog zatajenja srca.
15. Farmaceutska formulacija prema patentnom zahtjevu 14, naznačena time što je formulacija za oralnu primjenu.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361785763P | 2013-03-14 | 2013-03-14 | |
EP14719472.4A EP2968173B1 (en) | 2013-03-14 | 2014-03-14 | Heterocyclic compounds and their uses |
PCT/US2014/027104 WO2014152236A1 (en) | 2013-03-14 | 2014-03-14 | Heterocyclic compounds and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201967T1 true HRP20201967T1 (hr) | 2021-03-05 |
Family
ID=50549466
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191728 HRP20191728T1 (hr) | 2013-03-14 | 2019-09-24 | Sol omekamtiv mekarbila i postupak za pripravu soli |
HRP20201967TT HRP20201967T1 (hr) | 2013-03-14 | 2020-12-08 | Heterociklički spojevi i njihova uporaba |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191728 HRP20191728T1 (hr) | 2013-03-14 | 2019-09-24 | Sol omekamtiv mekarbila i postupak za pripravu soli |
Country Status (41)
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME03566B (me) | 2013-03-14 | 2020-07-20 | Amgen Inc | So omekamtiv mekarbila i proces za pripremanje soli |
TWI790189B (zh) | 2015-01-02 | 2023-01-21 | 美商梅拉洛伊卡公司 | 細菌組成物 |
JP6858716B2 (ja) | 2015-06-26 | 2021-04-14 | アムジエン・インコーポレーテツド | 心筋ミオシン活性化剤と洞房結節If電流阻害剤の併用療法 |
GEP20227340B (en) * | 2017-06-30 | 2022-01-25 | Amgen Inc | Synthesis of omecamtiv mecarbil |
JP2020526483A (ja) * | 2017-06-30 | 2020-08-31 | アムジエン・インコーポレーテツド | 心筋節活性化剤で心不全を治療する方法 |
EA039850B1 (ru) * | 2018-04-30 | 2022-03-21 | Эмджен Инк. | Синтез омекамтива мекарбила |
ES2815899T3 (es) * | 2018-07-09 | 2021-03-31 | Fis Fabbrica Italiana Sintetici Spa | 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo |
EP3820851A1 (en) | 2018-07-12 | 2021-05-19 | Assia Chemical Industries Ltd | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
MA53226A (fr) * | 2018-08-17 | 2021-11-24 | Amgen Inc | Sel et formes cristallines d'omecamtiv mecarbil |
CN114025845A (zh) * | 2019-03-12 | 2022-02-08 | 安进股份有限公司 | 心肌肌钙蛋白活化剂的多晶型物 |
AU2020234995A1 (en) * | 2019-03-12 | 2021-10-21 | Amgen Inc. | Polymorphs and cocrystals of a cardiac troponin activator |
WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
WO2021053189A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
EP4041198A4 (en) * | 2019-10-09 | 2023-08-16 | Dr. Reddy's Laboratories Limited | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF |
BR112022015457A2 (pt) * | 2020-02-10 | 2022-10-04 | Amgen Inc | Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido |
KR20230107282A (ko) | 2020-11-12 | 2023-07-14 | 암젠 인크 | 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법 |
WO2022177927A1 (en) * | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
MX2023010558A (es) | 2021-03-10 | 2023-11-24 | Amgen Inc | Sintesis de omecamtiv mecarbil. |
WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2788775B1 (fr) | 1999-01-22 | 2001-04-13 | Pf Medicament | Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique |
HUP0301242A3 (en) | 1999-12-23 | 2006-07-28 | Pfizer Prod Inc | Controlled release drug dosage form |
GB0124455D0 (en) * | 2001-10-11 | 2001-12-05 | Pfizer Ltd | Pharmaceutical formulations |
JP2005531492A (ja) | 2001-10-17 | 2005-10-20 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 高リスク患者のii型糖尿病を低減させる方法 |
US20050096365A1 (en) | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
PL1765327T3 (pl) * | 2004-06-17 | 2015-01-30 | Cytokinetics Inc | Związki, kompozycje i sposoby |
WO2007054975A1 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd | Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders |
PE20100743A1 (es) * | 2005-11-15 | 2010-11-25 | Glaxo Group Ltd | Nuevos procedimientos y formulaciones |
US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
AR058347A1 (es) * | 2005-12-15 | 2008-01-30 | Cytokinetics Inc | Entidades quimias composiciones y metodos |
WO2007078839A2 (en) * | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
US7639112B2 (en) | 2007-04-25 | 2009-12-29 | Sony Corporation | Fuse device with integrated switch |
US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
TW201006816A (en) * | 2008-05-15 | 2010-02-16 | Organon Nv | Hexafluoroisopropanol derivatives |
WO2010040110A1 (en) | 2008-10-03 | 2010-04-08 | Pericor Therapeutics, Inc. | Methods and compositions for treatment of acute heart failure |
US9253433B2 (en) | 2012-11-27 | 2016-02-02 | International Business Machines Corporation | Method and apparatus for tagging media with identity of creator or scene |
ME03566B (me) | 2013-03-14 | 2020-07-20 | Amgen Inc | So omekamtiv mekarbila i proces za pripremanje soli |
CA2902424A1 (en) * | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heterocyclic compounds and their uses |
WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
JP6858716B2 (ja) | 2015-06-26 | 2021-04-14 | アムジエン・インコーポレーテツド | 心筋ミオシン活性化剤と洞房結節If電流阻害剤の併用療法 |
JP2020526483A (ja) | 2017-06-30 | 2020-08-31 | アムジエン・インコーポレーテツド | 心筋節活性化剤で心不全を治療する方法 |
GEP20227340B (en) | 2017-06-30 | 2022-01-25 | Amgen Inc | Synthesis of omecamtiv mecarbil |
ES2815899T3 (es) | 2018-07-09 | 2021-03-31 | Fis Fabbrica Italiana Sintetici Spa | 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo |
EP3820851A1 (en) | 2018-07-12 | 2021-05-19 | Assia Chemical Industries Ltd | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
MA53226A (fr) | 2018-08-17 | 2021-11-24 | Amgen Inc | Sel et formes cristallines d'omecamtiv mecarbil |
US20220042055A1 (en) | 2018-12-18 | 2022-02-10 | Amgen Inc. | Method of reducing aromatic nitro compounds |
WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
WO2021053189A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
EP4041198A4 (en) | 2019-10-09 | 2023-08-16 | Dr. Reddy's Laboratories Limited | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF |
US20220411374A1 (en) | 2019-10-09 | 2022-12-29 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
BR112022015457A2 (pt) | 2020-02-10 | 2022-10-04 | Amgen Inc | Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido |
KR20230107282A (ko) | 2020-11-12 | 2023-07-14 | 암젠 인크 | 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법 |
WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
MX2023010558A (es) | 2021-03-10 | 2023-11-24 | Amgen Inc | Sintesis de omecamtiv mecarbil. |
-
2014
- 2014-03-14 ME MEP-2019-283A patent/ME03566B/me unknown
- 2014-03-14 EP EP20201011.2A patent/EP3821882A1/en active Pending
- 2014-03-14 CN CN201480018405.6A patent/CN105209437B/zh active Active
- 2014-03-14 CA CA2902646A patent/CA2902646C/en active Active
- 2014-03-14 WO PCT/US2014/027104 patent/WO2014152236A1/en active Application Filing
- 2014-03-14 HU HUE14720369A patent/HUE046285T2/hu unknown
- 2014-03-14 CN CN201480014897.1A patent/CN105120844A/zh active Pending
- 2014-03-14 SI SI201431724T patent/SI2968173T1/sl unknown
- 2014-03-14 CA CA2902436A patent/CA2902436A1/en active Pending
- 2014-03-14 RS RS20191313A patent/RS59536B1/sr unknown
- 2014-03-14 EA EA201591728A patent/EA031185B1/ru unknown
- 2014-03-14 AP AP2015008789A patent/AP2015008789A0/xx unknown
- 2014-03-14 BR BR112015023417-8A patent/BR112015023417B1/pt active IP Right Grant
- 2014-03-14 RS RS20201513A patent/RS61215B1/sr unknown
- 2014-03-14 UA UAA201509685A patent/UA117011C2/uk unknown
- 2014-03-14 CN CN201810812212.8A patent/CN108785265A/zh active Pending
- 2014-03-14 MY MYPI2015002299A patent/MY186048A/en unknown
- 2014-03-14 NZ NZ711225A patent/NZ711225A/en unknown
- 2014-03-14 PT PT147194724T patent/PT2968173T/pt unknown
- 2014-03-14 MX MX2015012414A patent/MX363347B/es unknown
- 2014-03-14 PE PE2015002000A patent/PE20151786A1/es unknown
- 2014-03-14 CA CA3147180A patent/CA3147180C/en active Active
- 2014-03-14 SG SG10201706656RA patent/SG10201706656RA/en unknown
- 2014-03-14 BR BR112015022857-7A patent/BR112015022857B1/pt active IP Right Grant
- 2014-03-14 HU HUE14719472A patent/HUE052355T2/hu unknown
- 2014-03-14 AU AU2014240049A patent/AU2014240049C1/en active Active
- 2014-03-14 KR KR1020227007907A patent/KR102474467B1/ko active IP Right Grant
- 2014-03-14 KR KR1020157025283A patent/KR102374159B1/ko active IP Right Grant
- 2014-03-14 LT LTEP14719472.4T patent/LT2968173T/lt unknown
- 2014-03-14 JP JP2016502336A patent/JP6498658B2/ja active Active
- 2014-03-14 US US14/210,713 patent/US9951015B2/en active Active
- 2014-03-14 DK DK14720369.9T patent/DK2970123T3/da active
- 2014-03-14 SI SI201431358T patent/SI2970123T1/sl unknown
- 2014-03-14 AR ARP140101155A patent/AR095542A1/es not_active Application Discontinuation
- 2014-03-14 RU RU2015143643A patent/RU2663663C2/ru active
- 2014-03-14 PL PL14719472T patent/PL2968173T3/pl unknown
- 2014-03-14 MA MA38399A patent/MA38399B2/fr unknown
- 2014-03-14 AU AU2014239995A patent/AU2014239995B2/en active Active
- 2014-03-14 MX MX2015012429A patent/MX2015012429A/es unknown
- 2014-03-14 JP JP2016502348A patent/JP6783138B2/ja active Active
- 2014-03-14 MA MA44637A patent/MA44637B1/fr unknown
- 2014-03-14 PL PL14720369T patent/PL2970123T3/pl unknown
- 2014-03-14 PT PT147203699T patent/PT2970123T/pt unknown
- 2014-03-14 UY UY0001035449A patent/UY35449A/es active IP Right Grant
- 2014-03-14 ES ES14720369T patent/ES2750676T3/es active Active
- 2014-03-14 EP EP14720369.9A patent/EP2970123B1/en active Active
- 2014-03-14 SG SG11201507258PA patent/SG11201507258PA/en unknown
- 2014-03-14 ES ES14719472T patent/ES2837038T3/es active Active
- 2014-03-14 US US14/773,436 patent/US9988354B2/en active Active
- 2014-03-14 WO PCT/US2014/027146 patent/WO2014152270A1/en active Application Filing
- 2014-03-14 DK DK14719472.4T patent/DK2968173T3/da active
- 2014-03-14 TW TW103109296A patent/TWI667026B/zh active
- 2014-03-14 LT LT14720369T patent/LT2970123T/lt unknown
- 2014-03-14 EP EP14719472.4A patent/EP2968173B1/en active Active
- 2014-03-16 JO JOP/2014/0114A patent/JOP20140114B1/ar active
-
2015
- 2015-08-24 IL IL240788A patent/IL240788B/en active IP Right Grant
- 2015-08-31 TN TN2015000380A patent/TN2015000380A1/en unknown
- 2015-09-03 IL IL24108915A patent/IL241089B/en active IP Right Grant
- 2015-09-08 PH PH12015501998A patent/PH12015501998A1/en unknown
- 2015-09-11 MX MX2021001231A patent/MX2021001231A/es unknown
- 2015-09-14 CL CL2015002708A patent/CL2015002708A1/es unknown
- 2015-09-14 SA SA515361088A patent/SA515361088B1/ar unknown
- 2015-10-13 CR CR20150549A patent/CR20150549A/es unknown
-
2016
- 2016-06-02 HK HK16106250.4A patent/HK1218080A1/zh unknown
- 2016-06-07 HK HK16106548.6A patent/HK1218512A1/zh unknown
- 2016-06-07 HK HK16106547.7A patent/HK1218544A1/zh unknown
- 2016-06-30 HK HK16107606.3A patent/HK1219484A1/zh unknown
-
2018
- 2018-03-20 US US15/926,411 patent/US10421726B2/en active Active
- 2018-04-26 US US15/963,529 patent/US20180312469A1/en not_active Abandoned
- 2018-11-15 JP JP2018214801A patent/JP6689942B2/ja active Active
-
2019
- 2019-01-24 PH PH12019500176A patent/PH12019500176A1/en unknown
- 2019-09-23 US US16/579,360 patent/US11384053B2/en active Active
- 2019-09-24 HR HRP20191728 patent/HRP20191728T1/hr unknown
- 2019-10-15 CY CY20191101080T patent/CY1122695T1/el unknown
- 2019-11-14 US US16/684,216 patent/US20200079736A1/en not_active Abandoned
-
2020
- 2020-04-08 JP JP2020069487A patent/JP6966590B2/ja active Active
- 2020-07-02 US US16/920,144 patent/US11472773B2/en active Active
- 2020-07-02 US US16/920,155 patent/US20200331859A1/en not_active Abandoned
- 2020-12-08 HR HRP20201967TT patent/HRP20201967T1/hr unknown
- 2020-12-15 CY CY20201101184T patent/CY1123633T1/el unknown
-
2021
- 2021-09-24 US US17/448,833 patent/US11958809B2/en active Active
- 2021-10-21 JP JP2021172324A patent/JP7174132B2/ja active Active
-
2022
- 2022-06-08 US US17/806,033 patent/US11884630B2/en active Active
- 2022-09-08 US US17/930,695 patent/US20230044617A1/en active Pending
-
2023
- 2023-11-27 US US18/520,156 patent/US20240101517A1/en active Pending
- 2023-12-06 US US18/531,424 patent/US20240217933A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201967T1 (hr) | Heterociklički spojevi i njihova uporaba | |
HRP20171518T1 (hr) | Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja | |
PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
HRP20211862T1 (hr) | Pripravci za i postupci liječenja anemije | |
EA201792224A1 (ru) | Композиции, содержащие ибрутиниб | |
JP2014167026A5 (hr) | ||
HRP20180889T1 (hr) | Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu | |
HRP20201140T1 (hr) | Oralna farmaceutska kompozicija | |
NZ628392A (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
AR100977A1 (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
TN2015000356A1 (en) | Bicyclic compounds | |
PH12017500261A1 (en) | Substituted bicyclic compounds | |
HRP20240045T1 (hr) | Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta | |
JP2016135782A5 (hr) | ||
WO2014144407A8 (en) | Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof | |
HRP20211761T1 (hr) | Dvokomponentna kompozicija koja sadrži acetilsalicilnu kiselinu | |
HRP20180315T1 (hr) | Čvrsti oblici soli alfa-6-mpeg6-o-hidroksikodona kao opioidni agonisti i njihove upotrebe | |
HRP20200196T1 (hr) | Fiziološki balansirane injektabilne formulacije fosnetupitanta | |
JP2015120758A5 (hr) | ||
RU2020115172A (ru) | Фармацевтическая композиция, содержащая хинолиновое производное | |
MX2015015681A (es) | Composicion farmaceutica que comprende fingolimod. | |
JP2016113441A (ja) | プラミペキソール二塩酸塩一水和物を含む放出が延長された錠剤 | |
EA202090965A1 (ru) | Водные композиции биластина | |
JP2014070061A5 (hr) |